117 related articles for article (PubMed ID: 19956857)
1. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Adema AD; Laan AC; Myhren F; Fichtner I; Verheul HM; Sandvold ML; Peters GJ
Int J Oncol; 2010 Jan; 36(1):285-94. PubMed ID: 19956857
[TBL] [Abstract][Full Text] [Related]
2. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues.
Sandvold ML; Galmarini C; Myhren F; Peters G
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):386-93. PubMed ID: 20544524
[TBL] [Abstract][Full Text] [Related]
3. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
Kano Y; Tanaka M; Akutsu M; Mori K; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1129-37. PubMed ID: 19306094
[TBL] [Abstract][Full Text] [Related]
4. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
7. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Bijman MN; Hermelink CA; van Berkel MP; Laan AC; Janmaat ML; Peters GJ; Boven E
Biochem Pharmacol; 2008 Jan; 75(2):427-37. PubMed ID: 17936723
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
12. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
14. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
17. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle arrest by oxaliplatin on cancer cells.
William-Faltaos S; Rouillard D; Lechat P; Bastian G
Fundam Clin Pharmacol; 2007 Apr; 21(2):165-72. PubMed ID: 17391289
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
